Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 156

Sort by

Sort Order Select

Journal Articles

RNA Sequencing of Hodgkin Lymphoma Reed-Sternberg Cells Uncovers a Plasma Cell Signature and Escape from NK Cell Recognition

Ethel Cesarman, MD PhD, Mikhail Roshal, MD PhD, Jonathan Reichel, PhD, Wagner Florian, PhD, Bhavneet Binder, Sakellarios Zairis, Jouliana Sadek, PhD, Joshua Brody, MD, Raul Rabadan, PhD, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 549.

https://doi.org/10.1182/blood-2019-131163

Published: 2019

Journal Articles

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Alison J. Moskowitz, MD, Ranjana H Advani, MD, Nancy L. Bartlett, MD, Julie M Vose, MDMBA, Radhakrishnan Ramchandren, MD, Tatyana A. Feldman, MD, Ann S. LaCasce, MD MMSc, Beth A. Christian, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, Lisa Brown, David Taft, Sahar Ansari, Daniel E. Zak, PhD, Mariana Sacchi, MD, Thomas Manley, MD, Alex F. Herrera, MD

Blood (2019) 134 (Supplement_1): 238.

https://doi.org/10.1182/blood-2019-122576

Published: 2019

Journal Articles

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

Ruetima Titapiwatanakun, MD, Sukhjeet Singh Batth, MD, Katherine Baker, NP, Wendy Tcheng, MD, Karen S. Fernandez, MD

Blood (2019) 134 (Supplement_1): 5298.

https://doi.org/10.1182/blood-2019-122973

Published: 2019

Journal Articles

BCL2 Expression Correlates with Refractory and Relapsed Classic Hodgkin Lymphoma. Its Blokeadge As a Promising Directed-Therapy

Angelica Gamboa-Cedeño, Cristaldo Nancy, MD, Victoria Otero, MD, Natalia Paola Schutz, MDMSc, Dorotea Fantl, MD, Maria Silvana Cugliari, Marta Zerga, MD, Rojas-Bilbao Erica, Hernán García Rivello, Federico Jauk, MD, Myriam Nuñez, PhD, Stella Maris Ranuncolo, MD PhD

Blood (2019) 134 (Supplement_1): 5282.

https://doi.org/10.1182/blood-2019-124452

Published: 2019

Journal Articles

Genomic Analysis of Hodgkin Lymphoma

Ralf Küppers, PhD

Blood (2019) 134 (Supplement_1): SCI-7.

https://doi.org/10.1182/blood-2019-121073

Published: 2019

Journal Articles

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Elisabetta Tedone, Paola Contini, Rosa Mangerini, Alessandra Bo, MD, Maria Carla De Luigi, MD, Paolo Carlier, MD, Alberto Serio, Paolo Strada, MD, Silvia Luchetti, Marco Gobbi, MD, Emanuela Marcenaro, PhD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 3231.

https://doi.org/10.1182/blood-2019-130740

Published: 2019

Journal Articles

Characterization of Myeloid-Derived Suppressor Cells and Tumor Associated Macrophages Using MultiOmyx TM Hyperplexed Immunofluorescence Assay in Hodgkin Lymphoma

Qingyan Au, PhD, Jun Fang, PhD, Anna Juncker-Jensen, PhD, Judy Kuo, Eric Leones, Flora Sahafi, RaghavKrishna Padmanabhan, PhD, Nicholas Hoe, PhD, Josette William, MD, PhD

Blood (2018) 132 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2018-99-115434

Published: 2018

Journal Articles

The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study

Khalid Nasser Al Hashmi, Kamla Alwahaibi, Murtadha K. Al-Khabori, BSc, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 5369.

https://doi.org/10.1182/blood-2018-99-114957

Published: 2018

Journal Articles

Refractory and Relapse Predictive Biomarkers in Hodgkin Lymphoma and Potential Directed-Therapy Targets

Angélica María Gamboa-Cedeño, Ms, Mariángeles Castillo, Victoria Otero, MD, Natalia Paola Schutz, MD, Dorotea Beatriz Fantl, MD, Federico Jauk, MD, Hernán García Rivello, Marta Zerga, MD, Silvana Cugliari, Erica Rojas-Bilbao, MD, Myriam Nuñez, PhD, Stella Ranuncolo, MD PhD

Blood (2018) 132 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2018-99-115062

Published: 2018

Journal Articles

Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group

Peter D Cole, MD, Menachem Spira, MD, Kathleen M McCarten, MD, Terzah M Horton, MD, Quinglin Pei, PhD, Monika Metzger, Richard A Drachtman, MD, Kara M. Kelly, MD

Blood (2017) 130 (Supplement 1): 2798.

https://doi.org/10.1182/blood.V130.Suppl_1.2798.2798

Published: 2017

Journal Articles

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

Christopher D. Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G. M. Roemer, Edward C. Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J. Freeman, Donna Neuberg, F. Stephen Hodi, Xiaole Shirley Liu, Margaret A. Shipp, Scott J. Rodig

Blood (2017) 130 (22): 2420–2430.

https://doi.org/10.1182/blood-2017-03-770719

Published: 2017

Includes: Supplemental data

Journal Articles

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F Herrera, MD, Nancy L Bartlett, MD, Radhakrishnan Ramchandren, MD, Julie M Vose, MD, Alison J Moskowitz, MD, Tatyana A Feldman, MD, Ann S LaCasce, MD, Stephen M Ansell, MD PhD, Craig H. Moskowitz, MD, Keenan Fenton, Kazunobu Kato, MD, Abraham Fong, MD PhD, Ranjana H Advani, MD

Blood (2016) 128 (22): 1105.

https://doi.org/10.1182/blood.V128.22.1105.1105

Published: 2016

Journal Articles

Impact of Treatment on IL-10, CTLA-4 and PD-L1 Gene Expression in Patients with Classical Hodgkin Lymphoma

Priscilla Brito Silva, MSc, Juliana Monte Real, PhD, Ludmila Rodrigues Pinto Ferreira, PhD, Gustavo Henrique Esteves, PhD, Joao Garibaldi Junior, MD, Adriana M. Damasco Penna, MD PhD, Fabio Nascimento Brito, MD, Egyla Cavalcante, MD, Otavio C. G. Baiocchi, MD PhD

Blood (2016) 128 (22): 5290.

https://doi.org/10.1182/blood.V128.22.5290.5290

Published: 2016

Journal Articles

Gene Networks and Canonical Pathways Analysis in Classical Hodgkin Lymphoma Patients

Priscilla Brito Silva, MSc, Juliana Monte Real, PhD, Otavio C. G. Baiocchi, MD PhD, Gustavo Henrique Esteves, PhD, Joao Garibaldi Junior, MD, Fabio Nascimento Brito, MD, Adriana M. Damasco Penna, MD PhD, Egyla Cavalcante, MD, Ludmila Rodrigues Pinto Ferreira, PhD

Blood (2016) 128 (22): 5298.

https://doi.org/10.1182/blood.V128.22.5298.5298

Published: 2016

Journal Articles

Management of Classical Hodgkin's Lymphoma: Single Center Experience from Tawam Hospital, United Arab Emirates

Hani Y Osman, Amar Lal, MD, Sabir Hussain, MD, Arif Alam, MBBS, Musab AbdAlrahman, MBBS

Blood (2016) 128 (22): 5363.

https://doi.org/10.1182/blood.V128.22.5363.5363

Published: 2016

Journal Articles

Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL)

Cristina Zannori, MD, Roberta Martiniani, MD, Stefano Ascani, MD, Fabrizio Liberati, MD, Annamaria Rauco, MD, Angelo Genua, MD, Anna Marina Liberati, MD

Blood (2016) 128 (22): 5364.

https://doi.org/10.1182/blood.V128.22.5364.5364

Published: 2016

Journal Articles

Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma

Layal el Halabi, Julien Adam, Virginie Marty, Jacques Bosq, MD, Julien Lazarovici, MD, Alina Danu, MD, Vincent Ribrag, MD, David Ghez, PhD MD

Blood (2016) 128 (22): 2952.

https://doi.org/10.1182/blood.V128.22.2952.2952

Published: 2016

Journal Articles

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Marco Ruella, MD, Michael Klichinsky, PharmD, Saad S Kenderian, MD, Olga Shestova, PhD, Amy Ziober, Michael D Feldman, MD, Mariusz A Wasik, MD, Carl H June, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 43.

https://doi.org/10.1182/blood.V128.22.43.43

Published: 2016

Journal Articles

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, Stephen Ansell, MD PhD, Joseph D. Rosenblatt, Kerry J. Savage, MDMSc, Joseph M. Connors, MD, Andreas Engert, Emily K Larsen, Dirk Huebner, Abraham Fong, Anas Younes, MD

Blood (2015) 126 (23): 2736.

https://doi.org/10.1182/blood.V126.23.2736.2736

Published: 2015

Journal Articles

Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma

Maciej Szydlowski, PhD, Monika Prochorec-Sobieszek, MD PhD, Anna Szumera-Cieckiewicz, MD PhD, Grazyna Hoser, PhD, Ewa Jablonska, PhD, Emilia Bialopiotrowicz, PhD, Przemyslaw Kiliszek, MSc, Tomasz Sewastianik, MSc, Anna Polak, MSc, Wojciech Czardybon, PhD, Michal Galezowski, PhD, Renata Windak, PhD, Krzysztof Brzozka, PhD, Krzysztof Warzocha, MD PhD, Jan Maciej Zaucha, MD PhD, Przemyslaw Juszczynski, MD PhD

Blood (2015) 126 (23): 819.

https://doi.org/10.1182/blood.V126.23.819.819

Published: 2015

NARROW

RNA Sequencing of Hodgkin Lymphoma Reed-Sternberg Cells Uncovers a Plasma Cell Signature and Escape from NK Cell Recognition

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma

BCL2 Expression Correlates with Refractory and Relapsed Classic Hodgkin Lymphoma. Its Blokeadge As a Promising Directed-Therapy

Genomic Analysis of Hodgkin Lymphoma

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Characterization of Myeloid-Derived Suppressor Cells and Tumor Associated Macrophages Using MultiOmyx TM Hyperplexed Immunofluorescence Assay in Hodgkin Lymphoma

The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study

Refractory and Relapse Predictive Biomarkers in Hodgkin Lymphoma and Potential Directed-Therapy Targets

Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Impact of Treatment on IL-10, CTLA-4 and PD-L1 Gene Expression in Patients with Classical Hodgkin Lymphoma

Gene Networks and Canonical Pathways Analysis in Classical Hodgkin Lymphoma Patients

Management of Classical Hodgkin's Lymphoma: Single Center Experience from Tawam Hospital, United Arab Emirates

Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL)

Strong Expression of the Immune Checkpoint Regulators LAG3 and Tim3 in Hodgkin Lymphoma

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only